https://doi.org/10.55788/d4871235
Dr Chia-Chun Chiang (Mayo Clinic, MN, USA) presented the results of one of the first studies to assess the patient perspective of telemedicine for headache care [1]. The AMF designed a standardised electronic questionnaire with 15 questions that was sent to over 100,000 AMF members to evaluate the period between March and September 2020. The results were published in Headache in May 2021 [2].
Included were 1,172 respondents. The average age was 49.5 years; 1,017 (88%) were women. Of 1,127 respondents, 648 (57.5%) said they had used telemedicine visits for headache care during the study period. Among this group, 553 patients (85.5%) used it for follow-up visits; 94 (14.5%) for new patient visits. Of 633 patients, only 47 (7.4%) received a new diagnosis of a headache disorder from telemedicine evaluation, the others did not have a change in their diagnoses. A new treatment was prescribed to 358 out of 636 patients (52.4%).
Of 638 participants, the experience using telemedicine for headache care was rated as very good by 396 (62.1%), good by 132 (20.7%), fair by 67 (10.5%), poor by 23 (3.6%), and other by 20 (3.1%). Most patients (89.8%) said they would continue to use telemedicine for their headache care and treatment, though half of them (45%) not for all visits. Among 524 respondents who did not use telemedicine visits, 293 (56%) said there was no need, but 255 (48.7%) said they were unaware that it was an option.
The study also revealed several barriers of care through telemedicine, including costs and availability. Dr Chiang said these challenges could be addressed by expanding insurance coverage to reimburse telemedicine, even after the pandemic, to widely promote and broadcast the use of telemedicine, and to consider internet access as a necessity and to expand internet service broadly in society.
- Chiang C-C, et al. Patient Experience of Telemedicine for Headache Care During the COVID-19 Pandemic: An American Migraine Foundation Survey Study. S4.010, AAN 2022, 02â07 April, Seattle, USA.
- Chiang C-C, et al. 2021;61(5):734â739.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« âWomen with epilepsy should be encouraged to breastfeedâ Next Article
Intranasal zavegepant safe and well tolerated in healthy adults »
« âWomen with epilepsy should be encouraged to breastfeedâ Next Article
Intranasal zavegepant safe and well tolerated in healthy adults »
Table of Contents: AAN 2022
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimerâs Disease and Other Dementias
Targeting senescent cells to treat age-related diseases
Cardiorespiratory fitness protects against dementia
Safety and effects of bosutinib in Lewy body dementia
Epilepsy
âWomen with epilepsy should be encouraged to breastfeedâ
Fenfluramine: possible new treatment for Lennox-Gastaut syndrome
Laser interstitial thermal therapy for refractory epilepsy
Migraine
Migraine may be an important obstetric risk factor
Intranasal zavegepant safe and well tolerated in healthy adults
Telemedicine during COVID-19 pandemic highly appreciated
Multiple Sclerosis
Ublituximab versus teriflunomide in relapsing MS patients
Ketogenic diet may improve disability and quality of life
Favourable additional safety data for ofatumumab
Predicting new T2 lesions using a machine learning algorithm
Evobrutinib reduces volume of slowly expanding lesions
Sustained long-term efficacy and safety of satralizumab in NMOSD
Muscle and Neuro-Muscular Disorders
Ravulizumab in patients with generalised myasthenia gravis
Gene therapy effective in older patients with spinal muscular atrophy
Losmapimod for facioscapulohumeral muscular dystrophy
SRP-9001 for treating patients with Duchenne muscular dystrophy
Cerebrovascular Disease and Stroke
Intravenous thrombolysis after ischaemic stroke: When in doubt, leave it out?
Better outcomes with mechanical thrombectomy in elderly stroke patients
Plasma NfL levels associated with cardiovascular risk
Non-invasive vagus nerve stimulation for acute stroke
Parkinsonâs Disease
Prasinezumab in Parkinsonâs disease: delayed-start analysis of PASADENA trial
IPX203 versus immediate release carbidopa-levodopa
Impact of COVID-19 public health interventions
COVID-19
Cognitive, EEG, and MRI features in COVID-19 survivors
Neurological manifestations of COVID-19 worsen prognosis
New evidence for biological basis of âCOVID-19 brain fogâ
Related Articles
August 18, 2021
Neural base of persistent hyposmia after COVID-19
September 7, 2023
New study characterises brain fog
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com